Membranoproliferative glomerulonephritis cost-effectiveness of therapy
Albeit, there is several strategies for treatment of MPGN, each method has its own indications, however, new medications such as monoclonal antibodies (Rituximab) is demonstrating new path for future treatment of MPGN[1]
References
- ↑ Michael Rudnicki (2017). “Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies”. Hindawi, BioMed Research International.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH